EPTIS
BAM Logo

PHLN: SARS-CoV-2 and other coronaviruses

EPTIS factsheet 794057 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts794057 https://www.eptis.bam.de/pts794057

PT provider
PT provider RCPAQAP RCPAQAP
Based in Australia
Language(s) English
Remarks Department of Health funded COVID-19 program. Three rounds of this module were offered in 2020 in response to the COVID-19 pandemic with plans for another in 2021. This module is suitable for all laboratory testing platforms that are utilised in the whole genome sequencing of SARS-CoV-2. Available free of charge to Australian public health laboratories that require the capability to test for SARS-CoV-2.
Keywords
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Inactivated virus for Whole genome sequencing Diluted SARS-CoV-2 (inactivated) Wet and dry lab analysis
Metagenomic sequence reads for Whole genome sequencing Diluted SARS-CoV-2 (inactivated) dry lab analysis
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (TBA cases/1 survey)
Year of first operation 2020
Contact details of the PT provider
Provider Contact person
RCPAQAP
Suite 201/8 Herbert Street
St Leonards, 2065
Australia

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21